Gedea Biotech selected for prestigious grant funding from the European Innovation Council, EIC
Yesterday, the EIC announced that Gedea Biotech has been selected for the €2.5M EIC Accelerator grant for the continued development and commercialization of pHyph, an antibiotic free treatment for vaginal infections. The funding will accelerate the development of pHyph, bringing this treatment…
The Swedish femtech company Gedea Biotech completes important clinical trial on vaginal fungal infection
The Swedish femtech company Gedea Biotech, which is developing an antibiotic-free treatment for vaginal infections, today announced that all patients in the EpHect study have been included and commenced treatment with pHyph. Results from the study are expected in the second quarter of this year.